NCT03135548 BI 655130.

Methods	Double‐blind, randomised, placebo‐controlled, phase IIa study Multi‐centre Period of inclusion: starting 30 May 2017
Participants	Inclusion criteria of the trial Male or female patients, 18 to 65 years of age at screening Palmoplantar pustulosis Further inclusion criteria apply Exclusion criteria of the trial Presence or known history of anti‐tumour necrosis factor (TNF)‐induced palmoplantar pustulosis (PPP)‐like disease Active or latent tuberculosis Further exclusion criteria apply
Interventions	Intervention 1 A: BI 655130 (low‐dose) 12 weeks of treatment Intervention 2 B: Placebo 12 weeks of treatment Intervention 3 C: BI 655130 (high‐dose) 12 weeks of treatment
Outcomes	Primary outcomes of the trial Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) 50 at week 16 (time frame: week 16) Number of patients with drug‐related adverse events (AEs) (time frame: up to 32 weeks) Secondary outcomes of the trial Treatment success defined as achieving a clinical response of 0 or 1 = clear/almost clear via Palmoplantar Pustulosis Physicians Global Assessment (PPPGA) at week 16 (time frame: week 16) Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) 75 at week 16 (time frame: week 16) Percentage change from baseline in the Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) at week 16 (time frame: baseline and week 16)
Notes	Sponsor: Boehringer Ingelheim

AE: adverse event.

PPP: palmoplantar pustulosis.

ppPASI: Palmoplantar Pustular Psoriasis Area and Severity Index.

PPPGA: Palmoplantar Pustulosis Physicians Global Assessment.

PUVA: combination of psoralens and long‐wave ultraviolet radiation.

RCT: randomised controlled trial.

TNF: tumour necrosis factor.